Sarepta (SPRT) volatility elevated into announcing FDA requesting more data up into FDA review of eteplirsen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'
June 7, 2016 9:08 AM EDTPiper Jaffray analyst Edward Tenthoff maintained an Underperform rating and $6 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA requested Sarepta provide additional dystrophin data from the ongoing confirmatory PROMOVI trial of eteplirsen. Sarepta plans to submit western blot data from biopsy... More
Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer
June 7, 2016 6:49 AM EDTOppenheimer analyst, Christopher Marai, reiterated his Outperform rating after Sarepta Therapeutic (NASDAQ: SRPT) announced the FDA has requested dystrophin data (n=13) from ongoing PROMOVI confirmatory trial of eteplirsen, prior to making an approval decision. SRPT indicated to us biopsies have been completed but... More
